Tag Archive for: radioligand therapy

UPDATE: Phase 1 Trial of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

/in , , /by

A new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]

Read more

OMNIRAY: a Phase 1 Clinical Trial for LY4257496 for mCRPC

/in , , /by

The OMNIRAY trial will be investigating LY4257496, a novel radioligand therapy and it is set to begin in August 2025. This phase 1a/1b, multicenter, open-label study aims to establish the safety, tolerability and dosimetry of LY4257496 in adult patients bearing advanced solid tumors that express the gastrin-releasing peptide receptor (GRPR). The trial proposes a two-part […]

Read more

Phase 1 Results for Imaging Agent Cu-61 NuriPro Shows Promise for Future Theranostic Option Cu-67

/in , , /by

At the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a promising phase I clinical trial results were presented for Cu-61 NuriPro, a next-generation PET imaging agent specifically designed for patients with PSMA-positive metastatic prostate cancer. This agent targets prostate-specific membrane antigen (PSMA), a protein commonly overexpressed in prostate cancer cells, making […]

Read more